AMGN Stock Down 13% in 3 Months: Buy the Dip or Book Profits?

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Open original source
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Open original source